reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other orphan protein misfolding disorders. reMYND is organized along two independently managed business units, the Contract Research Organization (CRO) and the own Drug Discovery & Development unit:
The in-vivo Contract Research Organization (CRO) helps its clients assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease in reMYND’s proprietary Alzheimer mouse models. Its mission is to be a strategic partner for its clients and help them identify the most promising set-up to assess potential effects.
Given the extensive experience fully focused on Alzheimer's, reMYND’s CRO can contribute its expertise for every type of Alzheimer treatment in any form of application.
The CRO is serving 6 of the Top 10 pharmaco’s worldwide and its client-base covers the US, Europe and Japan. The CRO has provided in-vivo proof-of-concept data for several candidate drugs that reMYND’s clients have currently in clinical development.